NCT05222100 Effect of Breast Implants om Mammography Screening
| NCT ID | NCT05222100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vastra Gotaland Region |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2021-05-12 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2021-05-12 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to survey how many women have breast implants in the mammography screening population and the effect of implants on the number and type of examinations and on costs.
Eligibility Criteria
Inclusion Criteria: * Women participating in the mammography screening program. Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05222100 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 75 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05222100 currently recruiting?
Yes, NCT05222100 is actively recruiting participants. Contact the research team at emma.em.hansson@vgregion.se for enrollment information.
Where is the NCT05222100 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT05222100 clinical trial?
NCT05222100 is sponsored by Vastra Gotaland Region. The trial plans to enroll 2,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.